Terms and Conditions

Pricing:
We make every effort to ensure that all the information contained within our price lists and quotes are complete and accurate. Quickscrews International Corporation reserves the right to make any changes or corrections to any information which may have been published in error. Part numbers, quantities, and weights are subject to change without notice.

Freight Policy:
All orders are FOB shipping origin. We reserve the right to ship orders from any of our warehouse locations at our discretion.
We offer our Distributor Partners the benefit of the only No Minimum "Drop- Ship" policy in our industry. Drop shipped orders will not be billed 3rd party or freight collect. Note that shipments made to branch locations within your own company are not deemed to be "drop shipments" but normal orders.

Notification of Errors:
Shipping errors must be documented in writing to our Customer Service department within 5 days of receipt of merchandise. We must be notified of any shortages within 5 days of receipt of merchandise. Shortages will not be credited unless noted on trucking company bill of lading at time of delivery. All requests need to be in writing. You may e-mail to: mhurd@quickscrews.com or fax to: 925-371-8267.

Returns:

All returns must have an RGA issued to receive credit. All products that are not deemed defective must be returned within 30 days of Invoice date. Returns can be subject up to a 30% Restocking charge. All requests must be in writing. You may request a return by e-mail to: mhurd@quickscrews.com or fax to: 925-371-8267

Carton Quantities/Weights:
We make every effort to ensure the published carton quantities and weights are accurate, but make no guarantees and such information is subject to change without notice.

Pak Quantities/Weights:
We make every effort to ensure the published pak quantities, paks per case, and weights are accurate, but make no guarantees and such information is subject to change without notice. We reserve the right to ship pak orders to the nearest full case quantities.

Warranty:
All products are produced to standard and commercial tolerances. We warranty products to be free from defects in materials and manufacturing. When we have determined that a product is defective, it will be replaced. At our discretion, a credit may be issued instead of replacement. Our liability is limited to the cost of the defective product only. No other warranty is implied.

Liability:
The customer shall be responsible for testing and verifying the suitability of the product for intended use. No warranty for intended use is implied. The customer assumes all risk and liability. Our only obligation is replacement or credit for product proven defective. We shall not be deemed liable for any loss or damage that may occur from the use or inability to use the product.

If you have any questions, please contact us at any time: E-Mail: gwiener@quickscrews.com

This Weeks News

Your rating: None (40 votes)
View archive pages >
nanosponge

Nanoengineers at the University of California, San Diego say they have created a "nanosponge" that is capable of safely removing a broad class of dangerous substances from the bloodstream - including toxins produced by MRSA, E. coli, venomous snakes, and bees.

In a study using the toxin from MRSA, inoculation with nanosponges enabled 89 percent of mice to survive lethal doses. The team has published details of their work in Nature Nanotechnology.

Researcher Liangfang Zhang said nanosponges can neutralize a range of pore-forming toxins, which destroy cells by poking holes in the cell membrane. Unlike other anti-toxin treatments that need to be custom synthesized for individual toxin type, the nanosponges can absorb different pore-forming toxins regardless of their molecular structures.

The nanosponge is made of a biocompatible polymer core wrapped in segments of red blood cell membrane, allowing it to evade the immune system and remain in circulation in the bloodstream while it collects the toxins.

The researchers are aiming to translate this work into approved therapies as quickly as possible. "One of the first applications we are aiming for would be an anti-virulence treatment for MRSA. That's why we studied one of the most virulent toxins from MRSA in our experiments," said co-researcher "Jack" Che-Ming Hu. The next step, he added, is to pursue clinical trials.